We believe, in the omics and AI era, a platform’s durable advantage is deeply rooted in the wet lab.
—Our numerous patented wet-lab innovations engineer superior data quality, sensitivity, and reproducibility—creating proprietary data that enable AI models to perform meaningfully better than models trained on standardized data from commercial platforms, and to remain defensible at scale.
We believe —
Our durable advantage comes from proprietary wet-lab procedures and pipelines that generate ultra-high-quality data inaccessible to others—enabling purpose-built AI that materially outperforms generic models trained on standardized commercial data.
— This organic combination keeps us defensible at scale.
Liquid & Tissue Biopsy | Disease Screening
Complete360®
Trademark Registration No. 7,778,754
Patent Issued: 12,540,946
Patent Pending: PCT/US24/62398; 63/643,536; 63/684,367; 63/686,953; 19/299,807; 19/198,934; 63/815,399; 19/309,422; 63/898,368; 63/898,378; 63/963,253; CN117597583; EP4308918; WO/2022/198071
Tissue Biopsy | Companion Diagnostics
Valid-NEO®
Trademark Registration NOA Serial #: 97,416,492
Patent Issued: 11,977,057 B2; 12,473,587 B2
Patent Pending: 3607065; 17/132,121; 63/038,816; 3607064; US2021-0389280; WO2018/186947; WO2021/252990; CN115698033; 40080610; 4165059; 40087334; ZL201880037683; ZL201880037641
Who We Are
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium
Meet Our Clients and Partners
Contact form
Have questions?
Get in touch!
We empower researchers, patients, and caregivers with clinically actionable insights.
